ecteinascidin 743 has been researched along with Cancer of Gastrointestinal Tract in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demetri, GD; Garcia-Carbonero, R; Harmon, D; Jimeno, J; Kuhlman, C; Maki, R; Manola, J; Merriam, P; Puchalski, T; Quigley, T; Ryan, DP; Supko, JG; Winkelman, J | 1 |
| Blay, JY; Bonvalot, S; Evrard, V; Hogendoorn, P; Jimeno, J; Judson, I; Le Cesne, A; Scurr, M; Seynaeve, C; van Glabbeke, M; Verweij, J | 1 |
2 trial(s) available for ecteinascidin 743 and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Prospective Studies; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2002 |
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Gastrointestinal Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2004 |